<DOC>
	<DOCNO>NCT02587195</DOCNO>
	<brief_summary>National , multicenter study : The study consist 3 period : 1 . A baseline visit confirm patient still CIS status . All patient clinically evaluate CDMS MRI ( less 2 month ) analyze exclude MS patient accord 2010 Mc Donald 's criterion . 2 . Treatment period time evaluation 3 . Post-treatment period : 4 week , 2 visit follow study drug discontinuation accelerate elimination procedure . All patient discontinue study drug accord investgator 's decision , perform accelerate elimination procedure post- accelerated elimination visit ( 2 4 week end treatment ( EOT ) .</brief_summary>
	<brief_title>A Study Evaluate Safety Long Term Treatment With Teriflunomide 14 mg Once Daily Patients With First Clinical Episode Suggestive Multiple Sclerosis Long-term Extension Period</brief_title>
	<detailed_description />
	<mesh_term>Sclerosis</mesh_term>
	<mesh_term>Multiple Sclerosis</mesh_term>
	<criteria>Patients enrol TOPIC study extension TOPIC study currently treat French extension TOPIC study convert MS. A baseline MRI scan ( perform less 2 month baseline Visit ) confirm patient still CIS status . Contraindication MRI , Clinically relevant cardiovascular , hepatic , neurological , endocrine , major systemic disease procedure/medication make implementation protocol interpretation study result difficult would put patient risk participate study Patients congenital acquire severe immunodeficiency , history cancer ( except basal squamous cell skin lesion surgically excise , evidence metastasis ) , lymphoproliferative disease , patient receive lymphoid irradiation Known history active tuberculosis adequately treat Persistent significant severe infection History drug alcohol abuse Patients must use Adrenocorticotrophic hormone ( ACTH ) systemic corticosteroid 2 week prior inclusion Prior use within 4 week inclusion concomitant use cholestyramine Prior concomitant use cladribine , mitoxantrone , immunosuppressant agent azathioprine , cyclophosphamide , cyclosporin , methotrexate mycophenolate Prior concomitant use interferon , cytokine therapy , glatiramer acetate intravenous immunoglobulin Prior concomitant use natalizumab ( Tysabri® ) Pregnant breastfeed woman Women childbearing potential protected effective contraceptive method birth control and/or unwilling unable test pregnancy . Women wish become pregnant course trial Patients significantly impair bone marrow function significant anemia , leukopenia , thrombocytopenia Human immunodeficiency virus ( HIV ) positive patient Persisting elevation ( confirm retest ) serum amylase lipase great 2fold upper limit normal Known history chronic pancreatic disease pancreatitis Liver function impairment persist elevation ( confirm retest ) serum glutamic pyruvic transaminase ( SGPT/ALT ) , serum glutamic oxaloacetic transaminase ( SGOT/AST ) , direct bilirubin great 1.5fold upper limit normal Known history active hepatitis Hypoproteinemia ( e.g. , case severe liver disease nephrotic syndrome ) serum albumin &lt; 3.0 g/dL Moderate severe impairment renal function , show serum creatinine &gt; 133 μmol/L ( &gt; 1.5 mg/dL )</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>55 Years</maximum_age>
	<verification_date>September 2015</verification_date>
	<keyword>Multiple Sclerosis</keyword>
</DOC>